Objective: The aim of this study was to investigate the anti-leukemic activity of the Bruton tyrosine kinase inhibitor Ibrutinib in combination with the small molecule MDM-2 inhibitor Nutlin-3 in preclinical models. Methods: The potential efficacy of the Ibrutinib/Nutlin-3 combination was evaluated in vitro in a panel of B leukemic cell lines (EHEB, JVM-2, JVM-3, MEC-1, MEC-2) and in primary B-chronic lymphocytic leukemia (B-CLL) patient samples, by assessing cell viability, cell cycle profile, apoptosis and intracellular pathway modulations. Validation of the combination therapy was assessed in a B leukemic xenograft mouse model. Results: Ibrutinib exhibited variable anti-leukemic activity in vitro and the combination with Nutlin-3 synergi...
The Bruton's tyrosine kinase protein is expressed in most hematopoietic cells with the exception of ...
Pharmacological agents that inhibit enzymes of the B-cell receptor (BCR) pathway are of increasing i...
The FDA-approved Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has significantly improved patie...
Objective: The aim of this study was to investigate the anti-leukemic activity of the Bruton tyrosin...
In B-chronic lymphocytic leukemia (B-CLL), the interaction between leukemic cells and the microenvir...
Abstract: Chronic lymphocytic leukemia (CLL) is characterized by progressive accumulation of nonfunc...
inhibits signaling and adhesion in response to CXCL12 and CXCL13 Th e phase 1 study of ibrutinib in...
Pediatric and adult patients with recurrent/refractory Burkitt lymphoma (BL) continue to have poor o...
Bruton’s tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages exc...
The activation of the B cell receptor (BCR) is nowadays known to play a primary role in the etiopath...
Aim: The Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is effective in patients wit...
The activation of the B cell receptor (BCR) is nowadays known to play a primary role in the etiopath...
Ibrutinib blocks B-cell receptor signaling and interferes with leukemic cell-tomicroenvironment inte...
Pediatric and adult patients with recurrent/refractory Burkitt lymphoma (BL) continue to have poor o...
Bruton’s tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is a novel targeted-therapeutic agen...
The Bruton's tyrosine kinase protein is expressed in most hematopoietic cells with the exception of ...
Pharmacological agents that inhibit enzymes of the B-cell receptor (BCR) pathway are of increasing i...
The FDA-approved Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has significantly improved patie...
Objective: The aim of this study was to investigate the anti-leukemic activity of the Bruton tyrosin...
In B-chronic lymphocytic leukemia (B-CLL), the interaction between leukemic cells and the microenvir...
Abstract: Chronic lymphocytic leukemia (CLL) is characterized by progressive accumulation of nonfunc...
inhibits signaling and adhesion in response to CXCL12 and CXCL13 Th e phase 1 study of ibrutinib in...
Pediatric and adult patients with recurrent/refractory Burkitt lymphoma (BL) continue to have poor o...
Bruton’s tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages exc...
The activation of the B cell receptor (BCR) is nowadays known to play a primary role in the etiopath...
Aim: The Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is effective in patients wit...
The activation of the B cell receptor (BCR) is nowadays known to play a primary role in the etiopath...
Ibrutinib blocks B-cell receptor signaling and interferes with leukemic cell-tomicroenvironment inte...
Pediatric and adult patients with recurrent/refractory Burkitt lymphoma (BL) continue to have poor o...
Bruton’s tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is a novel targeted-therapeutic agen...
The Bruton's tyrosine kinase protein is expressed in most hematopoietic cells with the exception of ...
Pharmacological agents that inhibit enzymes of the B-cell receptor (BCR) pathway are of increasing i...
The FDA-approved Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has significantly improved patie...